Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1965 1
1972 1
1973 1
1974 2
1975 5
1976 13
1977 7
1978 6
1979 9
1980 10
1981 15
1982 7
1983 13
1984 14
1985 10
1986 12
1987 15
1988 7
1989 10
1990 11
1991 14
1992 8
1993 11
1994 10
1995 9
1996 13
1997 11
1998 8
1999 12
2000 10
2001 13
2002 14
2003 12
2004 25
2005 21
2006 26
2007 24
2008 21
2009 22
2010 26
2011 38
2012 26
2013 27
2014 35
2015 35
2016 45
2017 49
2018 40
2019 43
2020 57
2021 50
2022 49
2023 44
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

946 results

Results by year

Filters applied: . Clear all
Page 1
Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis.
Kim ES, Frampton JE. Kim ES, et al. Drugs. 2016 Oct;76(15):1485-1492. doi: 10.1007/s40265-016-0643-7. Drugs. 2016. PMID: 27663245 Review.
Calcipotriol/betamethasone dipropionate foam (Enstilar()) is a once-daily synthetic vitamin D(3) analogue and synthetic corticosteroid fixed-dose combination foam formulation that is indicated for the topical treatment of plaque psoriasis in adults. In randomized, m …
Calcipotriol/betamethasone dipropionate foam (Enstilar()) is a once-daily synthetic vitamin D(3) analogue and synthetic cortic …
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data.
Megna M, Cinelli E, Camela E, Fabbrocini G. Megna M, et al. Expert Rev Clin Immunol. 2020 Jun;16(6):599-620. doi: 10.1080/1744666X.2020.1776116. Epub 2020 Jun 22. Expert Rev Clin Immunol. 2020. PMID: 32476507 Review.
Hence, topical therapy is the most frequent employed treatment in psoriasis also because it can be easily combined with systemic therapy. In this context, calcipotriol/betamethasone dipropionate (Cal/BD) fixed-dose association represents the first-line treatment due …
Hence, topical therapy is the most frequent employed treatment in psoriasis also because it can be easily combined with systemic therapy. In …
Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.
Yan R, Jiang S, Wu Y, Gao XH, Chen HD. Yan R, et al. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):135-44. doi: 10.4103/0378-6323.175919. Indian J Dermatol Venereol Leprol. 2016. PMID: 26924402 Free article. Review.
Topical calcipotriol/betamethasone dipropionate ointment/gel has been commonly used for the treatment of psoriasis vulgaris. ...The results showed that calcipotriol/betamethasone dipropionate was more effective than controls. A four-week treatment with …
Topical calcipotriol/betamethasone dipropionate ointment/gel has been commonly used for the treatment of psoriasis vulgaris. . …
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE).
Gerdes S, Velasco M, Wu JJ, Hubo M, Veverka KA. Gerdes S, et al. J Dermatolog Treat. 2021 Dec;32(8):883-893. doi: 10.1080/09546634.2020.1717417. Epub 2020 Jan 28. J Dermatolog Treat. 2021. PMID: 31986945 Review.
BACKGROUND: Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) in patients with psoriasis. In this review, we investigated whether such benefits could also be obtained in …
BACKGROUND: Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone …
Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis.
Taylor A, Singh R, Feldman SR. Taylor A, et al. Ann Pharmacother. 2023 Mar;57(3):341-347. doi: 10.1177/10600280221105508. Epub 2022 Jun 22. Ann Pharmacother. 2023. PMID: 35730211 Review.
OBJECTIVE: To review the pharmacokinetics, efficacy, and safety of recently approved calcipotriene and betamethasone dipropionate (C-BD) cream. DATA SOURCES: A literature review was conducted using MEDLINE (PubMed) and ClinicalTrials.gov from 2002 to mid-May 2022. . …
OBJECTIVE: To review the pharmacokinetics, efficacy, and safety of recently approved calcipotriene and betamethasone dipropionate …
Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.
McCormack PL. McCormack PL. Drugs. 2011 Apr 16;71(6):709-30. doi: 10.2165/11207300-000000000-00000. Drugs. 2011. PMID: 21504248 Review.
Calcipotriol/betamethasone dipropionate also improved health-related quality of life. ...Pharmacoeconomic analyses predicted calcipotriol/betamethasone dipropionate to be more cost effective than other topical therapies. ...
Calcipotriol/betamethasone dipropionate also improved health-related quality of life. ...Pharmacoeconomic analyses predicted c …
Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.
Frieder J, Kivelevitch D, Menter A. Frieder J, et al. Ther Deliv. 2017 Aug;8(9):737-746. doi: 10.4155/tde-2017-0058. Epub 2017 Jun 29. Ther Deliv. 2017. PMID: 28659016 Review.
Mainstay topical treatments include corticosteroids and vitamin D derivatives. Calcipotriene/betamethasone dipropionate aerosol foam is a novel single product combination, which seeks to provide superior therapeutic efficacy in addition to enhanced cosmetic properti …
Mainstay topical treatments include corticosteroids and vitamin D derivatives. Calcipotriene/betamethasone dipropionate aeroso …
Calcipotriol/betamethasone dipropionate for the treatment of psoriasis.
Charakida A, Dadzie O, Teixeira F, Charakida M, Evangelou G, Chu AC. Charakida A, et al. Expert Opin Pharmacother. 2006 Apr;7(5):597-606. doi: 10.1517/14656566.7.5.597. Expert Opin Pharmacother. 2006. PMID: 16553575 Review.
The two-compound product calcipotriol/betamethasone dipropionate is arising as a first-line treatment for mild-to-moderate plaque psoriasis. ...
The two-compound product calcipotriol/betamethasone dipropionate is arising as a first-line treatment for mild-to-moderate pla …
Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
McCormack PL. McCormack PL. Am J Clin Dermatol. 2011 Dec 1;12(6):421-4. doi: 10.2165/11207670-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21967117 Review.
Calcipotriene/betamethasone dipropionate also improved health-related quality of life. ...Pharmacoeconomic analyses predicted calcipotriene/betamethasone dipropionate to be more cost effective than other topical therapies. ...
Calcipotriene/betamethasone dipropionate also improved health-related quality of life. ...Pharmacoeconomic analyses predicted …
Betamethasone Dipropionate Nanocrystals: Investigation, Feasibility and In Vitro Evaluation.
Patel V, Mehta TA. Patel V, et al. AAPS PharmSciTech. 2022 Jul 14;23(6):197. doi: 10.1208/s12249-022-02346-1. AAPS PharmSciTech. 2022. PMID: 35835936
Corticosteroids, such as betamethasone dipropionate (BMD), have been the mainstay in topical therapy as potent glucocorticoid receptor agonist with immune suppression, anti-proliferative, and anti-inflammatory effects. ...
Corticosteroids, such as betamethasone dipropionate (BMD), have been the mainstay in topical therapy as potent glucocorticoid …
946 results